Germany and Denmark consider delaying second dose of covid-19 vaccine

▴ Germany and Denmark consider delaying second dose of covid-19 vaccine
With short-term efficacy from the first dose of the Pfizer-BioNTech vaccine approved scientists have suggested a longer gap between doses could be sensible.

Germany and Denmark could follow the UK’s plan to delay giving a second dose of Covid-19 vaccine to people who have already received a first jab, as frustration at the slow progress of European inoculation programmes continues to mount.

Britain said last week it would prioritise administering the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech shot so as to ensure more people were protected sooner, with a second dose coming 11 or 12 – rather than three – weeks later.

While the US has said it will not follow in the UK’s footsteps, it emerged on Monday that Germany’s health minister, Jens Spahn, had asked the country’s disease control agency, the Robert Koch Institute, to investigate postponing a second jab.

The move, which follows widespread criticism that Germany has failed to procure enough supplies of the vaccine and been unable to accelerate its nationwide inoculation campaign, was greeted with enthusiasm by doctors.

Leif Erik Sander, head of the vaccine research team at Berlin’s Charité hospital, said: “In view of the current scarcity of vaccines and the very high numbers of infections and hospitalisations in Germany, a strategy in which as many people as possible are vaccinated as early as possible is more effective.”

Denmark is also looking into extending the gap between jabs. The country’s infectious diseases institute said on Monday it would closely monitor the situation in Britain, with the health ministry reportedly considering a 3- to 6-week interval.

With short-term efficacy from the first dose of the Pfizer-BioNTech vaccine, the only one to have won approval from the European Medicines Agency so far, put at about 90%, scientists have suggested a longer gap between doses could be sensible.

Tags : #Germany #Denmark #UK #US #EMA #Prizef #BioNtech

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026